Hepatitis D Viremia Among Injection Drug Users in San Francisco
Hepatitis D Viremia Among Injection Drug Users in San Francisco
复制标题
DOI：
10.1093/infdis/jiy157
复制
发表时间：
2018-06-15
影响因子：
6.4
通讯作者：
O'Brien, Thomas R.
中科院分区：
文献类型：
--
作者：
Mahale, Parag;Aka, Peter, V;O'Brien, Thomas R.
注射吸毒者（PWID）通常暴露于乙型肝炎病毒（HBV）和丁型肝炎病毒（HDV）。我们使用一种新的定量微阵列抗体捕获（Q-MAC）试验、HDV western blot和HDV RNA来评估乙型肝炎表面抗原（HBsAg）阳性PWID （n = 73）中HDV病毒血症的患病率。HDV Q-MAC在该队列中表现良好：抗HDV， 100%的敏感性和特异性；HDV病毒血症，61.5%的敏感性和100%的特异性。35.6%的hbsag阳性参与者存在丁型肝炎病毒血症，与慢性丙型肝炎相比，在缓解型肝炎患者中更为常见(5.1% vs 0.6%；调整后优势比为9.80；P
People who inject drugs (PWID) are commonly exposed to hepatitis B virus (HBV) and hepatitis D virus (HDV). We evaluated the prevalence of HDV viremia among hepatitis B surface antigen (HBsAg)-positive PWID (n = 73) using a new quantitative microarray antibody capture (Q-MAC) assay, HDV western blot, and HDV RNA. HDV Q-MAC performed well in this cohort: anti-HDV, 100% sensitivity and specificity; HDV viremia, 61.5% sensitivity and 100% specificity. Hepatitis D viremia was present in 35.6% of HBsAg-positive participants and was more common in those with resolved compared to chronic hepatitis C (5.1% vs 0.6%; adjusted odds ratio, 9.80; P